Co-targeting of VEGFR2 and PD-L1 promotes survival and vasculature normalization in pleural mesothelioma

Pleural mesothelioma (PM) is an aggressive cancer caused by asbestos exposure, with limited treatment options and poor prognosis, highlighting the need for more effective therapies. Combining immune checkpoint blockade with anti-angiogenic therapy has shown potential in other cancers. Our study inve...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Sophie Rovers, Jonas Van Audenaerde, Ruben Verloy, Jorrit De Waele, Louize Brants, Christophe Hermans, Ho Wa Lau, Céline Merlin, Maria Möller Ribas, Peter Ponsaerts, Steven Van Laere, Filip Lardon, An Wouters, Scott A. Fisher, Jan van Meerbeeck, Elly Marcq, Evelien Smits
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Taylor & Francis Group 2025-12-01
Sarja:	OncoImmunology
Aiheet:	Anti-angiogenesis cancer immunotherapy combination therapy immune checkpoint blockade pleural mesothelioma
Linkit:	https://www.tandfonline.com/doi/10.1080/2162402X.2025.2512104
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!